Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321) subsidiary Zydus MedTech has partnered with Brazil-based Braile Biomedica to exclusively commercialize its Transcatheter Aortic Valve Implantation (TAVI) system in Europe, India, and select markets.
Under the agreement, Braile will manufacture and supply the TAVI system, while Zydus will handle commercialization and retain rights to manufacture select components, according to a Thursday filing with the Indian exchanges.
The deal marks Zydus MedTech's entry into the interventional cardiology segment, targeting the $6 billion global TAVI market, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.